A phase-1 single centric ENABLE clinical trial (NCT04049513) has been initiated using third-generation CD19 CAR (WZTL-002) incorporating the intracellular signaling domains of CD28 and Toll-like receptor 2 (TLR2) to identify a safety dose of R/R B cell NHL patients including MCL [177]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.